Review
Pharmacology & Pharmacy
Xiang Liu, Yuxuan Qiu, Duohui Li, Jiaxing Tan, Xiuping Liang, Wei Qin
Summary: This study aimed to compare the clinical outcomes and adverse events of three common urate-lowering therapy drugs in chronic kidney disease patients with hyperuricemia. The results indicated that there is insufficient evidence to support the renoprotective effects of the three drugs, but febuxostat showed a tendency to be superior to allopurinol in certain aspects. Additionally, febuxostat appeared to be a satisfactory alternative to allopurinol and benzbromarone in lowering urate and controlling blood pressure.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Xiang Yu, Mingjia Gu, Yiye Zhu, Lixiang Zhang, Wei Kong, Yanqin Zou
Summary: This study systematically evaluated the efficacy and safety of urate-lowering therapy in patients with chronic kidney disease (CKD). The results showed that urate-lowering therapy could reduce urate levels and potentially delay the decline of estimated glomerular filtration rate (eGFR). Febuxostat was found to be the most effective treatment in lowering urate levels. There were no significant differences in the incidence of adverse effects between groups.
CLINICAL THERAPEUTICS
(2022)
Article
Endocrinology & Metabolism
Mainak Banerjee, Rimesh Pal, Indira Maisnam, Subhankar Chowdhury, Satinath Mukhopadhyay
Summary: The use of SGLT2 inhibitors was found to significantly reduce the risk of gout in individuals with type 2 diabetes mellitus (T2DM) or heart failure (HF), and this effect was not dependent on baseline serum uric acid levels or the ability to lower serum uric acid. The metabolic and anti-inflammatory effects of SGLT2 inhibitors may primarily mediate their anti-gout benefits.
DIABETES OBESITY & METABOLISM
(2023)
Review
Pharmacology & Pharmacy
Xiuping Liang, Xiang Liu, Duohui Li, Wei Qin, Yi Liu
Summary: This meta-analysis aimed to assess the effectiveness and safety of urate-lowering therapy (ULT) for improving kidney function in patients with chronic kidney disease. The results showed that ULT effectively lowered serum uric acid levels, but its renoprotective effects were not significant.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Nutrition & Dietetics
Shima Abdollahi, Mahdi Vajdi, Fatemeh Meshkini, Azam Ahmadi Vasmehjani, Zohreh Sadat Sangsefidi, Cain C. T. Clark, Sepideh Soltani
Summary: A systematic review and meta-analysis showed that resveratrol supplementation has a mild renal protective effect in adults, but further studies are needed to evaluate its efficacy in patients with impaired renal function.
NUTRITION RESEARCH
(2023)
Review
Rheumatology
Shunichiro Tsukamoto, Naohito Okami, Takayuki Yamada, Kengo Azushima, Takahiro Yamaji, Sho Kinguchi, Kazushi Uneda, Tomohiko Kanaoka, Hiromichi Wakui, Kouichi Tamura
Summary: This systematic review examined the effects of different uric acid-lowering therapy (ULT) medications on kidney function in chronic kidney disease (CKD) patients. The results suggest that Topiroxostat and febuxostat may have better renoprotective effects compared to other ULT medications in CKD patients. Further large-scale, long-term studies are needed to confirm these findings and assess their impact on dialysis induction and major adverse cardiovascular events.
CLINICAL RHEUMATOLOGY
(2022)
Article
Multidisciplinary Sciences
Luc Molet-Benhamou, Kelly Virecoulon Giudici, Philipe de Souto Barreto, Christelle Cantet, Yves Rolland
Summary: This article examined the association between long-term use of urate-lowering therapies (ULT) and cognitive decline among community-dwelling older adults and found that ULT use was not associated with reduced cognitive decline over a 5-year follow-up. The study provides important insights into the relationship between cognitive function and urate-lowering therapies.
SCIENTIFIC REPORTS
(2022)
Article
Rheumatology
Angelo L. Gaffo, David A. Calhoun, Elizabeth J. Rahn, Suzanne Oparil, Peng Li, Tanja Dudenbostel, Daniel I. Feig, David T. Redden, Paul Muntner, Phillip J. Foster, Stephanie R. Biggers-Clark, Amy Mudano, Sebastian E. Sattui, Michael B. Saddekni, S. Louis Bridges, Kenneth G. Saag
Summary: This study found that urate-lowering therapy with allopurinol does not lower systolic blood pressure or high-sensitivity C-reactive protein levels in young adults, despite improvements in flow-mediated dilation. These findings do not support the use of urate lowering as a treatment for hypertension in young adults.
ARTHRITIS & RHEUMATOLOGY
(2021)
Article
Urology & Nephrology
Austin G. Stack, Nalina Dronamraju, Joanna Parkinson, Susanne Johansson, Eva Johnsson, Fredrik Erlandsson, Robert Terkeltaub
Summary: In patients with hyperuricemia and type 2 diabetes mellitus, treatment with verinurad combined with febuxostat lowered albuminuria levels and serum urate concentrations without impacting kidney function. Larger clinical studies are needed to definitively assess their combined impact on kidney preservation.
AMERICAN JOURNAL OF KIDNEY DISEASES
(2021)
Article
Rheumatology
Sunao Kojima, Kazuaki Uchiyama, Naoto Yokota, Eiichi Tokutake, Yutaka Wakasa, Shinya Hiramitsu, Masako Waki, Hideaki Jinnouchi, Hirokazu Kakuda, Takahiro Hayashi, Naoki Kawai, Masahiro Sugawara, Hisao Mori, Kenichi Tsujita, Kunihiko Matsui, Ichiro Hisatome, Yusuke Ohya, Kazuo Kimura, Yoshihiko Saito, Hisao Ogawa
Summary: Hyperuricaemia is a risk marker for cardiovascular and renal diseases, but excessive reduction of uric acid levels may be harmful. This study explored the feasibility of interventional treatments and determined the optimal uric acid level for asymptomatic hyperuricaemia patients.
Article
Medicine, General & Internal
Peng-Tzu Liu, Jong-Dar Chen
Summary: This study evaluated the association of HHcy and hyperuricemia with CKD in middle-aged and elderly populations in Taiwan, finding that both HHcy and hyperuricemia are independent risk factors for CKD with a significant synergistic association. The odds ratios of CKD increased with the quartiles of Hcy, independent of hyperuricemia, and hyperuricemia and HHcy showed a synergistic association with CKD.
Article
Dermatology
Kevin S. Kim, An-Wen Chan, Emilie P. Belley-Cote, Aaron M. Drucker
Summary: Noninferiority trials, which assess the comparability of a new treatment with the standard of care, have increased significantly in publication from 2005 to 2015. These trials differ from superiority trials in various aspects of trial design and have unique considerations.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Article
Multidisciplinary Sciences
Liyi Liu, Lili You, Kan Sun, Feng Li, Yiqin Qi, Chaogang Chen, Chuan Wang, Guojuan Lao, Shengneng Xue, Juying Tang, Na Li, Wanting Feng, Chuan Yang, Mingtong Xu, Yan Li, Li Yan, Meng Ren, Diaozhu Lin
Summary: This study found that lowering uric acid levels is associated with changes in renal function, reducing the risk of renal function decline and increasing the likelihood of renal function improvement. Management of serum uric acid levels should be emphasized in clinical practice, and it may be a part of chronic kidney disease treatment.
Review
Medicine, Research & Experimental
Juan Jose Garcia Sanchez, Juliette Thompson, David A. Scott, Rachel Evans, Naveen Rao, Elisabeth Sorstadius, Glen James, Stephen Nolan, Eric T. Wittbrodt, Alyshah Abdul Sultan, Bergur V. Stefansson, Dan Jackson, Keith R. Abrams
Summary: Contemporary data suggest that augmenting RAAS inhibitors with new drug classes has the potential to improve clinical outcomes in a broad range of patients with CKD.
ADVANCES IN THERAPY
(2022)
Article
Endocrinology & Metabolism
Chi Wang, Hebin Che, You Zhou, Ruiqing Wang, Di Zhu, Liting Cheng, Chongyou Rao, Qin Zhong, Zongren Li, Yongjie Duan, Jiayu Xu, Wei Dong, Yongyi Bai, Kunlun He
Summary: This retrospective cohort study investigated the joint association of hyperuricemia and chronic kidney disease (CKD) with mortality in patients with chronic heart failure (CHF). The results showed that both hyperuricemia and CKD were independently associated with increased in-hospital and long-term mortality risk in CHF patients. These findings highlight the importance of managing hyperuricemia and CKD together in the management of heart failure.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Urology & Nephrology
Xuemei Liu, Huifang Wang, Ruixia Ma, Leping Shao, Wei Zhang, Wei Jiang, Congjuan Luo, Tingting Zhai, Yan Xu
CLINICAL AND EXPERIMENTAL NEPHROLOGY
(2019)
Article
Urology & Nephrology
Chenyu Li, Long Zhao, Yanfei Wang, Lin Che, Hong Luan, Congjuan Luo, Yan Xu
Article
Engineering, Biomedical
Cong-Juan Luo, Feng Luo, Quan-Dong Bu, Wei Jiang, Wei Zhang, Xue-Mei Liu, Lin Che, Hong Luan, Hui Zhang, Rui-Xia Ma, Jian-Ping Sun, Yan Xu
BIOMEDICAL PAPERS-OLOMOUC
(2020)
Article
Physiology
Hang Liu, Long Zhao, Jisheng Zhang, Chenyu Li, Xuefei Shen, Xuemei Liu, Wei Jiang, Congjuan Luo, Yanfei Wang, Lin Che, Yan Xu
FRONTIERS IN PHYSIOLOGY
(2019)
Article
Cell Biology
Long Zhao, Chenyu Li, Bin Zhou, Congjuan Luo, Yanfei Wang, Lin Che, Jun Zhao, Yan Xu
Article
Nutrition & Dietetics
Chenyu Li, Lingyu Xu, Chen Guan, Long Zhao, Congjuan Luo, Bin Zhou, Xiaosu Zhang, Jing Wang, Jun Zhao, Junyan Huang, Dan Li, Hong Luan, Xiaofei Man, Lin Che, Yanfei Wang, Hui Zhang, Yan Xu
BRITISH JOURNAL OF NUTRITION
(2020)
Article
Urology & Nephrology
Lingyu Xu, Chenyu Li, Long Zhao, Bin Zhou, Congjuan Luo, Xiaofei Man, Hong Luan, Lin Che, Yanfei Wang, Yan Xu
Article
Pharmacology & Pharmacy
Guozheng Li, Chen Guan, Lingyu Xu, Lin Wang, Chengyu Yang, Long Zhao, Bin Zhou, Congjuan Luo, Hong Luan, Wei Jiang, Chenyu Li, Yan Xu
FRONTIERS IN PHARMACOLOGY
(2020)
Article
Nutrition & Dietetics
Xunliang Li, Hong Luan, Hui Zhang, Chenyu Li, Quandong Bu, Bin Zhou, Nina Tang, Haiyan Zhou, Yan Xu, Wei Jiang, Long Zhao, Xiaofei Man, Lin Che, Yanfei Wang, Congjuan Luo, Jianping Sun
Summary: This study demonstrated that early thiamine use in critically ill patients with acute kidney injury (AKI) is associated with reduced in-hospital mortality, improved 90-day mortality, and enhanced renal function recovery, especially in patients with stages 1 to 2 AKI.
BRITISH JOURNAL OF NUTRITION
(2022)
Article
Urology & Nephrology
Xueling Xu, Huifang Wang, Dandan Guo, Xiaofei Man, Jun Liu, Junying Li, Congjuan Luo, Ming Zhang, Li Zhen, Xuemei Liu
Summary: The study found that curcumin treatment in UAN rats can improve renal function, lower serum uric acid, creatinine, and BUN levels, alleviate renal pathological lesions and metabolic endotoxemia, and promote a balanced gut microbiota.
Article
Cell Biology
Long Zhao, Chenyu Li, Chen Guan, Ning Song, Hong Luan, Congjuan Luo, Wei Jiang, Quandong Bu, Yanfei Wang, Lin Che, Yan Xu
Summary: Studies have shown that in the early stage of acute kidney injury, the expression of SRF is significantly elevated, making it a potential early diagnostic biomarker. Analysis of microarray data related to kidney injury revealed a dramatic increase in SFR in mouse renal tissue 2-4 hours after ischemia/ reperfusion.
Article
Medicine, Research & Experimental
Feng Luo, Wei Jiang, Yan Xu, Xue-mei Liu, Wei Wang, Wei Zhang, Congjuan Luo
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
(2020)
Article
Biochemistry & Molecular Biology
Hui Dong, Yue Zhang, Yan Xu, Ruixia Ma, Liqiu Liu, Congjuan Luo, Wei Jiang
ACTA BIOCHIMICA ET BIOPHYSICA SINICA
(2019)
Article
Urology & Nephrology
Pei Zhang, Chen Guan, Chenyu Li, Zhihui Zhu, Wei Zhang, Hong Luan, Bin Zhou, Xiaofei Man, Lin Che, Yanfei Wang, Long Zhao, Hui Zhang, Congjuan Luo, Yan Xu